His brief, less than three-month tenure at CBER was marked most dramatically by the agency confronting Sarepta over patient deaths tied to its marketed Duchenne muscular dystrophy (DMD) gene therapy ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.